{"id":"https://genegraph.clinicalgenome.org/r/18ac5f9c-2d2b-40bb-9f2b-159908ac8a50v1.0","type":"EvidenceStrengthAssertion","dc:description":"GLS was first reported in relation to autosomal recessive glutaminase deficiency in 2018 (Lynch DS, et al., 2018, PMID: 29468182). Glutaminase deficiency is characterized by refractory seizures, respiratory failure, brain abnormalities and death in the neonatal period, though milder cases with spastic ataxia-dysarthria have also been reported. Evidence supporting this gene-disease relationship includes case-level data and experimental data. Five unique variants (nonsense, frameshift, and missense) have been reported as well as a 5â€™ UTR repeat expansion (normally occurring in 8 or 16 repeats) ranging from 680 to 1500 repeats. Variants in this gene have been reported in six probands in 3 publications (PMIDs: 29468182, 30575854, 30970188), and segregated with disease in at least 2 additional family member. Experimentally, this gene-disease relationship is supported by its role in the production of glutamate, the main excitatory neurotransmitter in the central nervous system, including the brain stem respiratory center (PMID: 12963351) and a mouse model with partial recapitulation of disease (PMID: 16641247). In summary GLS is definitively associated with autosomal recessive glutaminase deficiency.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/18ac5f9c-2d2b-40bb-9f2b-159908ac8a50","GCISnapshot":"https://genegraph.clinicalgenome.org/r/1eedd351-1520-4354-9608-cf8d56ce9bd9","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/1eedd351-1520-4354-9608-cf8d56ce9bd9_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2021-07-09T17:02:52.135Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/1eedd351-1520-4354-9608-cf8d56ce9bd9_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2021-07-09T17:01:41.305Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1eedd351-1520-4354-9608-cf8d56ce9bd9_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1eedd351-1520-4354-9608-cf8d56ce9bd9_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/96e4d280-9ac5-4a3b-9916-b5ff3ae1510b","type":"EvidenceLine","dc:description":"Common features of patients such as hypotonia, seizures, and brain abnormalities were not reported in the mice. Measurement of glutamine levels was not reported.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/84e9276d-d7b8-467c-aeff-a36e2e0fdd25","type":"Finding","dc:description":"GLS1 null mutants have an activity-dependent deficit in glutamatergic synaptic transmission resulting in altered respiratory rhythms and early goal-directed behavior. GLS1 null mutants failed to feed because of deficits in goal-directed behavior and died within the first postnatal day. This has some similarity to patients with glutaminase deficiency, with respiratory insufficiency and neonatal death.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16641247","rdfs:label":"GLS1-/- Mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1eedd351-1520-4354-9608-cf8d56ce9bd9_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0efb81af-d175-46d9-8a53-2cc968d2ef44","type":"EvidenceLine","dc:description":"Glutaminase plays a pivotal role in the production of glutamate, the main excitatory neurotransmitter in the central nervous system, including the brain stem respiratory center. In the central nervous system, GLS activity is proposed to generate a significant amount of the total neuronal glutamate pool that in turn acts as an excitatory neurotransmitter. GLS1 activity may therefore be essential for the optimal function of multiple central nervous system glutamate receptors and their downstream roles in both the normal and pathological brain, consistent with the phenotypes seen in patients.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b1759382-fd5e-4eca-bb22-696acd2bca4d","type":"Finding","dc:description":"The enzymatic function of GLS in conversion of glutamine to glutamate, is consistent with the elevated glutamine observed in patients. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12963351","rdfs:label":"Glutaminase Activity","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1eedd351-1520-4354-9608-cf8d56ce9bd9_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d3fafbae-7979-4f88-a58b-74118fdb984b_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Compound heterozygous variants were identified in this patient with glutaminase deficiency; functional analyses in lymphocytes and fibroblasts showed markedly reduced GLS activity. A maternally inherited nonsense variant Tyr308Ter, in exon 6 of 18, was found to have no glutaminase activity when expressed in HEK293 cells, and is expected to result in NMD. Tyr308Ter is present in one allele in gnomAD (MAF of 0.000008810 in the European population). The paternal allele includes a triplet repeat expansion (GCA)1500 in the 5' UTR, which normally occurs in either 8 or 16 repeats.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e5957aba-a9e6-4753-9d44-33dbd7e11e62","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30970188","rdfs:label":"Patient 3","detectionMethod":"Trio WES. Sanger sequencing to confirm nonsense variant. Triplet repeat-primed PCR and GLS repeat PCR assays to confirm repeat expansions","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"2209 uM glutamine (reference: 405-781 uM)","phenotypes":["obo:HP_0001337","obo:HP_0001252","obo:HP_0002194","obo:HP_0032894","obo:HP_0001272","obo:HP_0003217","obo:HP_0001260"],"previousTesting":true,"previousTestingDescription":"negative urea cycle disorders gene panel","secondTestingMethod":"PCR","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d3fafbae-7979-4f88-a58b-74118fdb984b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30970188","allele":[{"id":"https://genegraph.clinicalgenome.org/r/2efee882-3310-4335-b3f5-d65593c0c896","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"A preferred title is not available","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CACN137730323"}},{"id":"https://genegraph.clinicalgenome.org/r/b363a8b6-494a-43c9-bbb1-057badad8f14","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014905.4(GLS):c.923dup (p.Tyr308Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/626336"}}],"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/fae01b5b-3ebd-4c11-b18f-4cf8e318ff86_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The compound heterozygous variants Arg272Lys and Gln81Ter were identified in this patient with glutaminase deficiency (consistent with the significantly increased glutamine level, z score 11.7). The nonsense variant occurs in exon 1 of 18 and is predicted to undergo NMD. The Arg272 variant is suggested to play a role in stabilization of the protein fold so Arg272Lys may thereby reduce the amount of active GLS, however functional evidence was not provided.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/84527f23-63ae-430a-9b54-cc3cf9c03065","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30575854","rdfs:label":"2-1","detectionMethod":"Trio WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"pathological cardiotocography","phenotypes":["obo:HP_0001250","obo:HP_0001336","obo:HP_0009879","obo:HP_0000496","obo:HP_0012420","obo:HP_0002169","obo:HP_0001284","obo:HP_0010851","obo:HP_0012196","obo:HP_0002878","obo:HP_0003217","obo:HP_0001252"],"secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/fae01b5b-3ebd-4c11-b18f-4cf8e318ff86_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30575854","allele":[{"id":"https://genegraph.clinicalgenome.org/r/a3e7e03b-8cf9-452a-acb1-60f876004794","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014905.4(GLS):c.241C>T (p.Gln81Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/618997"}},{"id":"https://genegraph.clinicalgenome.org/r/494bf5d3-569c-4a78-bc1a-37d312f60465","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014905.4(GLS):c.815G>A (p.Arg272Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/618998"}}],"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/cad57328-030b-4e60-bcf5-f7c83529bfd6_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Compound heterozygous variants were identified in this patient with glutaminase deficiency; functional analyses in lymphocytes and fibroblasts showed markedly reduced GLS activity. A paternally inherited missense variant Pro313Leu was found to have 2.8% glutaminase activity when expressed in HEK293 cells. The maternal allele includes a triplet repeat expansion (GCA)680 (GRCh38 (chr2:190880873-190880896)x84) in the 5' UTR which normally occurs in either 8 or 16 repeats.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/52cd26fd-e87f-4ce8-83ae-3905884c879f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30970188","rdfs:label":"Patient 1","detectionMethod":"Trio WES and WGS in the proband. Sanger sequencing to confirm missense variant. Triplet repeat-primed PCR and GLS repeat PCR assays to confirm repeat expansions","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"1800 uM glutamine (reference: 405-781 uM)","phenotypes":["obo:HP_0003217","obo:HP_0002194","obo:HP_0000750","obo:HP_0002066"],"previousTesting":true,"previousTestingDescription":"negative urea cycle disorders gene panel","secondTestingMethod":"PCR","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/cad57328-030b-4e60-bcf5-f7c83529bfd6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30970188","allele":[{"id":"https://genegraph.clinicalgenome.org/r/205b7a38-81be-4515-ab80-697d93bfef8f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014905.4(GLS):c.938C>T (p.Pro313Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/626334"}},{"id":"https://genegraph.clinicalgenome.org/r/5100d8ed-3c1c-460a-8bd2-654283954edf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"A preferred title is not available","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CACN137728710"}}],"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c995cc31-1fb4-47b5-9f26-e17efac13f45_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous frameshift variant c.695dup creates an early stop codon in exon 4 of 18 and is predicted to result in NMD, consistent with the significantly increased (z score 3.2) glutamine levels observed in the patient.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/62f452a3-c221-470c-afcd-ef3dcbeb25a2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30575854","rdfs:label":"Family 1-2","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"detectionMethod":"Exome sequencing with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"inadequate reaction to external stimuli","phenotypes":["obo:HP_0002093","obo:HP_0010851","obo:HP_0002406","obo:HP_0001320","obo:HP_0002171","obo:HP_0002079","obo:HP_0003217","obo:HP_0009879","obo:HP_0002033","obo:HP_0025102","obo:HP_0012695","obo:HP_0001336","obo:HP_0002069","obo:HP_0001252","obo:HP_0002365"],"previousTesting":true,"previousTestingDescription":"results of metabolic newborn screening were unremarkable","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/c995cc31-1fb4-47b5-9f26-e17efac13f45_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30575854","allele":{"id":"https://genegraph.clinicalgenome.org/r/c5844207-b6d1-4c33-a6e1-505b989c51a1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256310.2(GLS):c.695dup (p.Asp232fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/618996"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1eedd351-1520-4354-9608-cf8d56ce9bd9_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a7fd3b94-4833-4ec3-bd3c-1404f380e453_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29468182","rdfs:label":"Lynch Family","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/a7fd3b94-4833-4ec3-bd3c-1404f380e453","type":"Family","rdfs:label":"Lynch Family","member":{"id":"https://genegraph.clinicalgenome.org/r/322fab4c-c8d5-448c-98db-5767744ce03e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29468182","rdfs:label":"Patient 1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":7,"detectionMethod":"Reanalyzed the WGS data for CNVs in regions of homozygosity to identify the 8 kb duplication spanning exon 1 of GLS. Duplication specific PCR was used to confirm the duplication and map breakpoints.","firstTestingMethod":"Whole genome shotgun sequencing","phenotypes":["obo:HP_0007064","obo:HP_0000648","obo:HP_0000572","obo:HP_0002493","obo:HP_0001310","obo:HP_0002497","obo:HP_0001348","obo:HP_0001272","obo:HP_0002509","obo:HP_0000640","obo:HP_0001260"],"previousTesting":true,"previousTestingDescription":"An extensive series of tests for childhood neurodegenerative diseases was negative including metabolic testing for Batten's Disease and Neuronal Ceroid Lipofuscinosis. WES on both affected family members did not identify any potentially disease-causing mutations. WGS on patient 1 also failed to identify any likely pathogenic variants. CytoSNP12 genotyping array on all available family members to identify regions of homozygosity. ","secondTestingMethod":"PCR","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e74754c0-7c79-4715-89fd-df9cf6667807_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29468182","allele":{"id":"https://genegraph.clinicalgenome.org/r/a28dc459-af3c-405d-b21d-5c6b7bd74c89","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"A preferred title is not available","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CACN137641540"}},"paternityMaternityConfirmed":"none"}}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002497","obo:HP_0000648","obo:HP_0002493","obo:HP_0001348","obo:HP_0001260","obo:HP_0001310","obo:HP_0002509","obo:HP_0000640","obo:HP_0001272","obo:HP_0007064","obo:HP_0000572"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/322fab4c-c8d5-448c-98db-5767744ce03e"}},{"id":"https://genegraph.clinicalgenome.org/r/648f1ab1-4444-49ed-8bad-a09e014a496a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30575854","rdfs:label":"Family 2","estimatedLodScore":1.1,"family":{"id":"https://genegraph.clinicalgenome.org/r/648f1ab1-4444-49ed-8bad-a09e014a496a","type":"Family","rdfs:label":"Family 2","member":{"id":"https://genegraph.clinicalgenome.org/r/84527f23-63ae-430a-9b54-cc3cf9c03065"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":4,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002878","obo:HP_0009879","obo:HP_0003217","obo:HP_0010851"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/84527f23-63ae-430a-9b54-cc3cf9c03065"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/bffe9440-9a44-4834-8671-e7ccf9d32a23_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Compound heterozygous variants were identified in this patient with glutaminase deficiency; functional analyses in lymphocytes and fibroblasts showed markedly reduced GLS activity. The maternal and paternal alleles each include a triplet repeat expansion (GCA)1400 and (GCA)900 respectively, in the 5' UTR, which normally occurs in either 8 or 16 repeats.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/20e45339-bc8c-4003-8e8e-90e7caf8448b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30970188","rdfs:label":"Patient 2","detectionMethod":"Triplet repeat-primed PCR and GLS repeat PCR assays to confirm repeat expansions.","firstTestingMethod":"PCR","phenotypeFreeText":"2000 uM glutamine (reference: 405-781 uM)","phenotypes":["obo:HP_0002194","obo:HP_0002066","obo:HP_0003217","obo:HP_0000750"],"previousTesting":true,"previousTestingDescription":"negative urea cycle disorders gene panel","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/bffe9440-9a44-4834-8671-e7ccf9d32a23_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30970188","allele":[{"id":"https://genegraph.clinicalgenome.org/r/92d1b667-3296-4d53-8ad5-2b576c5458b1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"A preferred title is not available","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CACN137729646"}},{"id":"https://genegraph.clinicalgenome.org/r/552a46d3-1b50-4ff5-ade2-9eb57adcb20c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"A preferred title is not available","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CACN137729754"}}],"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/e74754c0-7c79-4715-89fd-df9cf6667807_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous duplication of exon 1 (GRCh38 (chr2:190877353-190885295)x3) leads to a premature stop codon predicted to result in NMD, consistent with RT-PCR results which found GLS cDNA was not present in the patient.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/322fab4c-c8d5-448c-98db-5767744ce03e"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":9.5}],"evidenceStrength":"Definitive","sequence":3093,"specifiedBy":"GeneValidityCriteria7","strengthScore":11.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/VRE-q6nE_Oo","type":"GeneValidityProposition","disease":"obo:MONDO_0600001","gene":"hgnc:4331","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_1eedd351-1520-4354-9608-cf8d56ce9bd9-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}